| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly is at the forefront of product development, focusing on innovative treatments such as gene therapy and weight-loss medications, including Mounjaro and Zepbound. The recent FDA approval of Omvoh for ulcerative colitis exemplifies the company's commitment to addressing serious health issues. Positive clinical trial results further bolster their reputation for effective new therapies. This strong emphasis on innovation is a testament to Eli Lilly's leadership in the pharmaceutical industry. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0.2 on 2025-10-30. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (4.4) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-30 | 1%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.8 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | 7 | |||||||
| 2025-10-28 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | 5.5 | |||||||
| 2025-10-27 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-10-26 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-10-25 | 0%(0%) | 0 | 0% | 0.4 | 3.4 | -1 | |||||||
| 2025-10-24 | 0%(0%) | 0 | 0% | 0.5 | 3.9 | 6 | |||||||
| 2025-10-23 | 0%(0%) | 0 | 0% | 0.3 | 2.8 | -1 | |||||||
| 2025-10-22 | 0%(0%) | 0 | 0% | 0.2 | 2.4 | -1 | |||||||
| 2025-10-21 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-10-30 17:50:07 The significant sales growth of Eli Lilly's weight-loss products showcases successful product development and market acceptance. |
| 2025-10-30 17:50:07 The article notes high demand for weight-loss drugs Zepbound and Mounjaro, reflecting a growing trend in the pharmaceutical industry. |
| 2025-10-30 17:50:07 The article discusses Eli Lilly's increased guidance due to soaring sales, indicating a strong positive outlook on company earnings. |
| 2025-10-30 17:01:51 A recent partnership with Walmart to distribute Eli Lilly’s drugs at discounted prices is anticipated to enhance market reach and accessibility. |
| 2025-10-30 17:01:51 Following the earnings report, Eli Lilly's stock saw a notable increase, reflecting positive investor sentiment and confidence. |
| 2025-10-30 17:01:51 Eli Lilly raised its full-year sales and earnings outlook based on the positive performance in its weight-loss drug segment. |
| 2025-10-30 17:01:51 The demand for Eli Lilly's weight-loss treatments, Mounjaro and Zepbound, significantly contributed to the company's revenue surge. |
| 2025-10-30 17:01:51 Eli Lilly reported strong Q3 earnings that exceeded analyst expectations, showcasing robust revenue growth driven by sales of its weight-loss drugs. |
| 2025-10-30 15:48:42 The introduction and growth of GLP-1 medications highlight Eli Lilly's commitment to innovation in the pharmaceutical industry. |
| 2025-10-30 15:48:42 Analysts are raising their price targets for Eli Lilly, reflecting positive sentiment about the company's recent earnings performance. |
| 2025-10-30 15:48:42 Eli Lilly's collaboration with Walmart aims to enhance consumer access to its GLP-1 medications, reflecting strategic growth through partnerships. |
| 2025-10-30 15:48:42 Eli Lilly reported a significant increase in sales of its weight-loss drugs, indicating strong financial performance and market demand. |
| 2025-10-30 11:49:37 The bidding war initiated by Novo Nordisk for Metsera Inc. illustrates the competitive nature of the pharmaceutical industry. |
| 2025-10-30 11:49:37 Eli Lilly's significant revenue growth from its obesity and diabetes treatments indicates strong performance in the pharmaceutical market. |
| 2025-10-30 09:36:26 The increasing acceptance and demand for weight-loss drugs indicate a significant trend within the healthcare market, aligning with consumer health demands. |
| 2025-10-30 09:36:26 The surge in Eli Lilly's stock price is attributed to strong earnings and optimistic guidance driven by drug sales. |
| 2025-10-30 09:36:26 Eli Lilly is focused on maintaining its competitive edge against rivals like Novo Nordisk in the growing market for obesity and diabetes medications. |
| 2025-10-30 09:36:26 Eli Lilly has raised its full-year forecast, reflecting confidence in its continued financial performance due to booming drug sales. |
| 2025-10-30 09:36:26 Eli Lilly is experiencing significant growth in sales and profitability driven by strong demand for its weight-loss drugs, particularly Zepbound and Mounjaro. |